{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:44:10Z","timestamp":1785789850298,"version":"3.56.0"},"reference-count":26,"publisher":"The Journal of Health Economics and Outcomes Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JHEOR"],"abstract":"<jats:p>Objectives: To understand treatment patterns, healthcare resource utilization, and costs of care among patients with spinal muscular atrophy (SMA).\n\nMethods: SMA patients were identified from a large managed care population using administrative claims data from January 2006 to March 2016. Patients were classified into infantile, childhood-onset, and late-onset groups based on age of first SMA diagnosis. They were matched 1:1 to non-SMA patients based on age, gender, geography, and health plan type.\n\nResults: In the infantile group, 17.4% and 26.1% were treated with invasive and non-invasive ventilation, respectively. Uses of orthotics\/orthoses and orthopedic surgery were frequent: 54.5% and 22.7% childhood group; 27.0% and 38.5% late-onset group. Mean per member per month costs in SMA vs. matched non-SMA patients was $25,517 vs. $406 (infantile); $6,357 vs. $188 (childhood-onset); $2,499 vs. $742 (late-onset).\n\nConclusions: SMA patients, particularly with infantile onset, incurred significantly higher healthcare utilization and costs than the general population.<\/jats:p>","DOI":"10.36469\/63185","type":"journal-article","created":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T21:05:08Z","timestamp":1575493508000},"page":"185-195","source":"Crossref","is-referenced-by-count":18,"title":["Healthcare Utilization, Costs of Care, and Mortality Among Patients With Spinal Muscular Atrophy"],"prefix":"10.36469","volume":"6","author":[{"given":"Hiangkiat","family":"Tan","sequence":"first","affiliation":[{"name":"HealthCore, Inc., Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Gu","sequence":"additional","affiliation":[{"name":"HealthCore, Inc., Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Er","family":"Chen","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeshwari","family":"Punekar","sequence":"additional","affiliation":[{"name":"HealthCore, Inc., Wilmington, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perry B.","family":"Shieh","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of California Los Angeles School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22273","published-online":{"date-parts":[[2019,12,2]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"D\u2019Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet J Rare Dis. 2011;6(71).","DOI":"10.1186\/1750-1172-6-71"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Mesfin A, Sponseller PD, Leet AI. Spinal muscular atrophy: manifestations and management. J Am Acad Orthop Surg. 2012;20(6):393-401.","DOI":"10.5435\/JAAOS-20-06-393"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Ogino S, Leonard DG, Rennert H, Ewens WJ, Wilson RB. Genetic risk assessment in carrier testing for spinal muscular atrophy. Am J Med Genet. 2002;110(4):301-307.","DOI":"10.1002\/ajmg.10425"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Armstrong EP, Malone DC, Yeh WS, Dahl GJ, Lee RL, Sicignano N. The economic burden of spinal muscular atrophy. J Med Econ. 2016;19(8):822-826.","DOI":"10.1080\/13696998.2016.1198355"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Farrar MA, Carey KA, Paguinto S-G, Chambers G, Kasparian NA. Financial, opportunity and psychosocial costs of spinal muscular atrophy: an exploratory qualitative analysis of Australian carer perspectives. BMJ Open. 2018;8(5):e020907. doi:10.1136\/bmjopen-2017-020907","DOI":"10.1136\/bmjopen-2017-020907"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Qian Y, McGraw S, Henne J, Jarecki J, Hobby K, Yeh WS. Understanding the experiences and needs of individuals with Spinal Muscular Atrophy and their parents: a qualitative study. BMC Neurol. 2015;15(217).","DOI":"10.1186\/s12883-015-0473-3"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Rouault F, Christie-Brown V, Broekgaarden R, et al. Disease impact on general well-being and therapeutic expectations of European Type II and Type III spinal muscular atrophy patients. Neuromuscul Disord. 2017;27(5):428-438.","DOI":"10.1016\/j.nmd.2017.01.018"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Cardenas J, Menier M, Heltzer MD, Sproule DM. High healthcare resource use in hospitalized patients with a diagnosis of spinal muscular atrophy type 1: retrospective analysis of the Kids\u2019 Inpatient Database (KID). Pharmacoecon. 2019:205-213.","DOI":"10.1007\/s41669-018-0093-0"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Lee M, Franca UL, Graham RJ, McManus ML. Pre-nusinersen hospitalization costs of children with spinal muscular atrophy. Pediatr Neurol. 2019;92:3-5.","DOI":"10.1016\/j.pediatrneurol.2018.11.002"},{"key":"ref9","unstructured":"Cure SMA. Types of SMA. http:\/\/www.curesma.org\/sma\/about-sma\/types-of-sma\/."},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Mercuri E, Finkel RS, Muntoni F, et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28(2):103-115.","DOI":"10.1016\/j.nmd.2017.11.005"},{"key":"ref11","unstructured":"Muscular Dystrophy Association. Spinal muscular atrophy: types of SMA. https:\/\/www.mda.org\/disease\/spinal-muscular-atrophy\/types."},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Wang CH, Finkel RS, Bertini ES, et al. Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol. 2007;22(8):1027-1049.","DOI":"10.1177\/0883073807305788"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Larkindale J, Yang W, Hogan PF, et al. Cost of illness for neuromuscular diseases in the United States. Muscle Nerve. 2014;49(3):431-438.","DOI":"10.1002\/mus.23942"},{"key":"ref14","unstructured":"Lewin Group. Cost of amyotrophic lateral sclerosis, muscular dystrophy, and spinal muscular atrophy in the United States. http:\/\/staging2.mda.org\/sites\/default\/files\/Cost. Published 2012."},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Lopez-Bastida J, Pena-Longobardo LM, Aranda-Reneo I, Tizzano E, Sefton M, Oliva-Moreno J. Social\/economic costs and health-related quality of life in patients with spinal muscular atrophy (SMA) in Spain. Orphanet J Rare Dis. 2017;12(1).","DOI":"10.1186\/s13023-017-0695-0"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Klug C, Schreiber-Katz O, Thiele S, et al. Disease burden of spinal muscular atrophy in Germany. Orphanet J Rare Dis. 2016;11(1).","DOI":"10.1186\/s13023-016-0424-0"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Farrar MA, Kiernan MC. The Genetics of Spinal Muscular Atrophy: Progress and Challenges. Neurotherapeutics. 2015;12(2):290-302.","DOI":"10.1007\/s13311-014-0314-x"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Malone DC, Dean R, Arjunjir , et al. Cost-effectiveness analysis of using onasemnogene abeparvovec (AVXS-101) in spinal muscular atrophy type 1 patients. J Market Access Health Policy. 2019;7(1601484).","DOI":"10.1080\/20016689.2019.1601484"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Dabbous O, Maru B, Jansen JP, et al. Survival, motor function, and motor milestones: comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy type 1. Adv Ther. 2019(36):1164-1176.","DOI":"10.1007\/s12325-019-00923-8"},{"key":"ref20","unstructured":"Wasser T, Wu B, Ycas J, Tunceli O. Applying weighting methodologies to a commercial database to project US Census demographic data. Am J Account Care. 2015;3:33-38."},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Finkel RS, Mercuri E, Meyer OH, et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul Disord. 2018;28(3):197-207.","DOI":"10.1016\/j.nmd.2017.11.004"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle Nerve. 2015;51(2):157-167.","DOI":"10.1002\/mus.24497"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Kaufmann P, McDermott MP, Darras BT, et al. Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology. 2012;79(18):1889-1897.","DOI":"10.1212\/WNL.0b013e318271f7e4"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Kolb SJ, Coffey CS, Yankey JW, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82(6):883-891.","DOI":"10.1002\/ana.25101"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Jeppesen J, Madsen A, Marquardt J, Rahbek J. Living and ageing with spinal muscular atrophy type 2: observations among an unexplored patient population. *Dev Neurorehabil*. 2010;13(1):10-18.","DOI":"10.3109\/17518420903154093"}],"container-title":["Journal of Health Economics and Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/pmid\/32685590\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T14:40:30Z","timestamp":1748875230000},"score":1,"resource":{"primary":{"URL":"https:\/\/jheor.org\/article\/10824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,2]]},"references-count":26,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,5,3]]}},"URL":"https:\/\/doi.org\/10.36469\/63185","archive":["Portico","Portico"],"relation":{},"ISSN":["2327-2236"],"issn-type":[{"value":"2327-2236","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,2]]},"article-number":"10824"}}